Search

Your search keyword '"Chrétien, Marie‐Lorraine"' showing total 92 results
Start Over Author "Chrétien, Marie‐Lorraine"
92 results on '"Chrétien, Marie‐Lorraine"'

2. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Author

Schavgoulidze, Anaïs, Talbot, Alexis, Perrot, Aurore, Cazaubiel, Titouan, Leleu, Xavier, Manier, Salomon, Buisson, Laure, Mahéo, Sabrina, Do Souto Ferreira, Laura, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Avet-Loiseau, Hervé, and Corre, Jill

Published
2023
Full Text
View/download PDF

3. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Published
2022
Full Text
View/download PDF

4. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Author

Cazaubiel, Titouan, Leleu, Xavier, Perrot, Aurore, Manier, Salomon, Buisson, Laure, Maheo, Sabrina, Do Souto Ferreira, Laura, Lannes, Romain, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Schavgoulidze, Anais, Avet-Loiseau, Herve, and Corre, Jill

Published
2022
Full Text
View/download PDF

5. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author

Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Published
2018
Full Text
View/download PDF

6. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Author

Heiblig, Maël, Rea, Delphine, Chrétien, Marie-Lorraine, Charbonnier, Aude, Rousselot, Philippe, Coiteux, Valérie, Escoffre-Barbe, Martine, Dubruille, Viviane, Huguet, Françoise, Cayssials, Emilie, Hermet, Eric, Guerci-Bresler, Agnès, Amé, Shanti, Sackmann-Sala, Lucila, Roy, Lydia, Sobh, Mohamad, Morisset, Stéphane, Etienne, Gabriel, and Nicolini, Franck E.

Published
2018
Full Text
View/download PDF

7. BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Author

Cornillon, Jérôme, Daguenet, Elisabeth, Bay, Jacques-Olivier, Chauchet, Adrien, Salles, Gilles, Contentin, Nathalie, Nicolas-Virelizier, Emmanuelle, Mercier, Mélanie, Vallet, Nicolas, Alexis, Magda, Chrétien, Marie-Lorraine, Cluzeau, Thomas, Huynh, Anne, Himberlin, Chantal, Dorvaux, Véronique, Amorim, Sandy, Lejeune, Caroline, de Latour, Régis Peffault, and Gyan, Emmanuel

Published
2019
Full Text
View/download PDF

8. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Author

Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, and Avet-Loiseau, Herve

Published
2016
Full Text
View/download PDF

10. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study

Author

Talbot, Alexis, primary, Bobin, Arthur, additional, Tabone, Léa, additional, Lambert, Jérôme, additional, Boccaccio, Catherine, additional, Deal, Cécile, additional, Petillon, Marie-Odile, additional, Allangba, Olivier, additional, Agape, Philippe, additional, Arnautou, Pierre, additional, Belkhir, Rakiba, additional, Cailleres, Sylvie, additional, Chaoui, Driss, additional, Chrétien, Marie-Lorraine, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Frenzel, Laurent, additional, Gastaud, Lauris, additional, Huart, Antoine, additional, Hulin, Cyrille, additional, Karlin, Lionel, additional, Laribi, Kamel, additional, Le Calloch, Ronan, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Manier, Salomon, additional, Montes, Lydia, additional, Moreau, Stéphane, additional, Moreau, Philippe, additional, Morel, Véronique, additional, Norwood, James, additional, Piocelle, Frédérique Orsini, additional, Perrot, Aurore, additional, Pica, Gian Matteo, additional, Rey, Philippe, additional, Schmitt, Anna, additional, Stoppa, Anne-Marie, additional, Tiab, Mourad, additional, Touzeau, Cyrille, additional, Vidal, Valérie, additional, Vignon, Marguerite, additional, Vincent, Laure, additional, Van De Wyngaert, Zoé, additional, Zarnitsky, Charles, additional, Kerbouche, Naima, additional, Paka, Prani, additional, Leleu, Xavier, additional, Arnulf, Bertrand, additional, Avet-Loiseau, Hervé, additional, and Du Myélome, IFM: Intergroupe Francophone, additional

Published
2023
Full Text
View/download PDF

11. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Author

Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, and Avet-Loiseau, Hervé

Published
2015
Full Text
View/download PDF

12. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Author

Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, and Avet-Loiseau, Herve

Published
2015
Full Text
View/download PDF

14. Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Author

Dumas, Pierre-Yves, Raffoux, Emmanuel, Berard, Emilie, Bertoli, Sarah, Hospital, Marie Anne, Heiblig, Mael, Desbrosses, Yohan, Bonmati, Caroline, Pautas, Cecile, Lambert, Juliette, Orvain, Corentin, Banos, Anne, Pasquier, Florence, Peterlin, Pierre, Marchand, Tony, Uzunov, Madalina, Frayfer, Jamilé, Turlure, Pascal, Cluzeau, Thomas, Jourdan, Eric, Himberlin, Chantal, Tavernier, Emmanuelle, Villate, Alban, Haiat, Stéphanie, Chretien, Marie-Lorraine, Carre, Martin, Chantepie, Sylvain, Vaida, Iona, Wemeau, Mathieu, Chebrek, Safia, Guillerm, Gaëlle, Guieze, Romain, Debarri, Houria, Gehlkopf, Eve, Laribi, Kamel, Marçais, Ambroise, Santagostino, Alberto, Bene, Marie C, Mineur, Ariane C, Pigneux, Arnaud, Dombret, Herve, and Recher, Christian

Published
2022
Full Text
View/download PDF

15. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04

Author

Touzeau, Cyrille, Perrot, Aurore, Hulin, Cyrille, Manier, Salomon, Macro, Margaret, Chrétien, Marie-Lorraine, Karlin, Lionel, Decaux, Olivier, Jacquet, Caroline, Tiab, Mourad, Leleu, Xavier, Planche, Lucie, Avet-Loiseau, Hervé, Moreau, Philippe, Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Nancy (CHU Nancy), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), CIC - Poitiers, and Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience

Published
2022

16. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study

Author

Caillot, Leo, Sleiman, Emmanuel, Lafon, Ingrid, Chretien, Marie-Lorraine, Gueneau, Pauline, Payssot, Alexandre, Pedri, Romain, Lakomy, Daniela, Bailly, François, Guy, Julien, Quenot, Jean-Pierre, Avet-Loiseau, Herve, and Caillot, Denis

Published
2024
Full Text
View/download PDF

17. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, Attal, Michel, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Abstract

High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.

Published
2022

18. Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome

Author

Baumelou, Marion, primary, Payssot, Alexandre, additional, Row, Celine, additional, Racine, Jessica, additional, Lafon, Ingrid, additional, Bastie, Jean‐Noél, additional, Chevreux, Steeve, additional, Chrétien, Marie‐Lorraine, additional, Maynadié, Marc, additional, Caillot, Denis, additional, and Guy, Julien, additional

Published
2022
Full Text
View/download PDF

20. Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21)

Author

Burlet, Bénédicte, primary, Ramla, Selim, additional, Fournier, Cyril, additional, Abrey-Recalde, Maria Jimena, additional, Sauter, Camille, additional, Chrétien, Marie-Lorraine, additional, Rossi, Cédric, additional, Duffourd, Yannis, additional, Ragot, Sylviane, additional, Buriller, Céline, additional, Tournier, Benjamin, additional, Chapusot, Caroline, additional, Nadal, Nathalie, additional, Racine, Jessica, additional, Guy, Julien, additional, Bailly, François, additional, Martin, Laurent, additional, Casasnovas, Olivier, additional, Bastie, Jean-Noël, additional, Caillot, Denis, additional, Albuisson, Juliette, additional, Broccardo, Cyril, additional, Thieblemont, Catherine, additional, Delva, Laurent, additional, Maynadié, Marc, additional, Aucagne, Romain, additional, and Callanan, Mary B., additional

Published
2021
Full Text
View/download PDF

21. B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL

Author

Fournier, Benjamin, primary, Balducci, Estelle, additional, Duployez, Nicolas, additional, Clappier, Emmanuelle, additional, Cuccuini, Wendy, additional, Arfeuille, Chloé, additional, Caye-Eude, Aurélie, additional, Delabesse, Eric, additional, Bottollier-Lemallaz Colomb, Elodie, additional, Nebral, Karin, additional, Chrétien, Marie-Lorraine, additional, Derrieux, Coralie, additional, Cabannes-Hamy, Aurélie, additional, Dumezy, Florent, additional, Etancelin, Pascaline, additional, Fenneteau, Odile, additional, Frayfer, Jamile, additional, Gourmel, Antoine, additional, Loosveld, Marie, additional, Michel, Gérard, additional, Nadal, Nathalie, additional, Penther, Dominique, additional, Tigaud, Isabelle, additional, Fournier, Elise, additional, Reismüller, Bettina, additional, Attarbaschi, Andishe, additional, Lafage-Pochitaloff, Marina, additional, and Baruchel, André, additional

Published
2019
Full Text
View/download PDF

23. OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis

Author

Lannes, Romain, Samur, Mehmet, Perrot, Aurore, Mazzotti, Celine, Divoux, Marion, Cazaubiel, Titouan, Schavgoulidze, Anaïs, Chretien, Marie-Lorraine, Manier, Salomon, Adiko, Didier, Orsini-Piocelle, Frederique, Lifermann, François, Brechignac, Sabine, Gastaud, Lauris, Bouscary, Didier, Macro, Margaret, Cleynen, Alice, Mohty, Mohamad, Munshi, Nikhil, Corre, Jill, and Avet-Loiseau, Hervé

Published
2022
Full Text
View/download PDF

24. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Author

Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, Facon, Thierry, Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, and Facon, Thierry

Abstract

Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

25. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Richez, Valentine, additional, Guidez, Stéphanie, additional, Duhamel, Alain, additional, Machuron, François, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jean-Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Pétillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chrétien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos-Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric G., additional, Attal, Michel, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional

Published
2019
Full Text
View/download PDF

26. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis

Author

Sevin, Margaux, primary, Kubovcakova, Lucia, additional, Pernet, Nicolas, additional, Causse, Sébastien, additional, Vitte, Franck, additional, Villeval, Jean Luc, additional, Lacout, Catherine, additional, Cordonnier, Marine, additional, Rodrigues-Lima, Fernando, additional, Chanteloup, Gaétan, additional, Mosca, Matthieu, additional, Chrétien, Marie-Lorraine, additional, Bastie, Jean Noël, additional, Audia, Sylvain, additional, Sagot, Paul, additional, Ramla, Selim, additional, Martin, Laurent, additional, Gleave, Martin, additional, Mezger, Valérie, additional, Skoda, Radek, additional, Plo, Isabelle, additional, Garrido, Carmen, additional, Girodon, François, additional, and de Thonel, Aurélie, additional

Published
2018
Full Text
View/download PDF

27. Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

Author

Nakamura, Kyohei, primary, Kassem, Sahar, additional, Cleynen, Alice, additional, Chrétien, Marie-Lorraine, additional, Guillerey, Camille, additional, Putz, Eva Maria, additional, Bald, Tobias, additional, Förster, Irmgard, additional, Vuckovic, Slavica, additional, Hill, Geoffrey R., additional, Masters, Seth L., additional, Chesi, Marta, additional, Bergsagel, P. Leif, additional, Avet-Loiseau, Hervé, additional, Martinet, Ludovic, additional, and Smyth, Mark J., additional

Published
2018
Full Text
View/download PDF

28. CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts

Author

Saint-Paul , Laetitia, Nguyen , Chi-Hung, Buffière , Anne, Barros , Jean-Paul Pais de, Hammann , Arlette, Landras-Guetta , Corinne, Filomenko , Rodolphe, Chrétien , Marie-Lorraine, Johnson , Pauline, Bastie , Jean-Noël, Delva , Laurent, Quéré , Ronan, de Barros , Jean-Paul Pais, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer ( LabEx LipSTIC ), Institut National de la Recherche Agronomique ( INRA ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Université Paris-Sud - Paris 11 ( UP11 ) -École pratique des hautes études ( EPHE ) -Institut Gustave Roussy ( IGR ) -Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Université de Bourgogne ( UB ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université de Franche-Comté ( UFC ), Plateforme Lipidomique [Dijon] ( LAP ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -IFR100 - Structure fédérative de recherche Santé-STIC-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Plateforme cytométrie en flux [Fédération de Recherche Santé STIC de l’Université de Bourgogne], Université de Bourgogne ( UB ) -IFR100 - Structure fédérative de recherche Santé-STIC, Institut Curie, UMR9187-U1196, CMIB, CNRS-INSERM, Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Life Sciences Institute (University of British Columbia), and University of British Columbia ( UBC )

Subjects
lipid rafts, CD45 phosphatase, [ SDV.BC ] Life Sciences [q-bio]/Cellular Biology, hemic and lymphatic diseases, oncogenic transformation, hematopoietic cells, lipids (amino acids, peptides, and proteins), acute myeloid leukemia, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

IF 5.008; International audience; CD45 is a pan-leukocyte protein with tyrosine phosphatase activity involved in the regulation of signal transduction in hematopoiesis. Exploiting CD45 KO mice and lentiviral shRNA, we prove the crucial role that CD45 plays in acute myeloid leukemia (AML) development and maintenance. We discovered that CD45 does not colocalize with lipid rafts on murine and human non-transformed hematopoietic cells. Using a mouse model, we proved that CD45 positioning within lipid rafts is modified during their oncogenic transformation to AML. CD45 colocalized with lipid rafts on AML cells, which contributes to elevated GM-CSF signal intensity involved in proliferation of leukemic cells. We furthermore proved that the GM-CSF/Lyn/Stat3 pathway that contributes to growth of leukemic cells could be profoundly affected, by using a new plasma membrane disrupting agent, which rapidly delocalized CD45 away from lipid rafts. We provide evidence that this mechanism is also effective on human primary AML samples and xenograft transplantation. In conclusion, this study highlights the emerging evidence of the involvement of lipid rafts in oncogenic development of AML and the targeting of CD45 positioning among lipid rafts as a new strategy in the treatment of AML.

Published
2016

29. Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM

Author

Royer, Bruno, Stéphane, Minvielle, Diouf, Momar, Roussel, Murielle, Karlin, Lionel, Hulin, Cyrille, Arnulf, Bertrand, Macro, Margaret, Sylvie, Cailleres, Brion, Annie, Bréchignac, Sabine, Karim, Beladj, Chrétien, Marie Lorraine, Wetterwald, Marc, Chaleteix, Carine, Tiab, Mourad, Leleu, Xavier, Frenzel, Laurent, Garderet, Laurent, Choquet, Sylvain, Fuzibet, Jean-Gabriel, Dauriac, Charles, Forneker, Luc-Matthieu, Benboubker, Lotfi, Facon, Thierry, Moreau, Philippe, Avet-Loiseau, Hervé, Marolleau, Jean-Pierre, CHU Amiens-Picardie, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de l'Innovation et Recherche Clinique, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital universitaire de Lyon, Hôpital Universitaire de Lyon, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Universitaire de Caen, Hôpital Général Aix en Provence, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Universitaire de Bobigny, Hôpital Universitaire de Créteil, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Général de Dunkerque, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Hôpital Général de La Roche sur Yon, Facteurs de persistance des cellules leucémique - Equipe 3 (INSERM U 837), Service des Maladies du Sang, Hôpital Huriez, CHU Necker - Enfants Malades [AP-HP], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département Universitaire Nice, Hôpital de Nice, Service Hématologie, CHU Pontchaillou [Rennes], Hôpital universitaire de Strasbourg, Hôpital Universitaire de Tours, Hôpital Claude Huriez [Lille], CHU Lille, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service clinique des Maladies du Sang, Bernardo, Elizabeth, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Hôpital Universitaire de Toulouse

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; PurposePrimary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance.Patients and MethodsPatients 70 years old and younger with newly diagnosed pPCL received four alternating cycles of bortezomib, dexamethasone plus doxorubicin or cyclophosphamide. Peripheral blood stem cells were collected from responding patients with < 1% of circulating plasma cells before HDM/ASCT. As consolidation, young patients received a reduced-intensity conditioning allograft, whereas the remaining patients underwent a second HDM/ASCT followed by 1 year of bortezomib, lenalidomide, dexamethasone. The primary end point was progression-free survival (PFS).ResultsForty patients (median age, 57 years; range, 27 to 71 years) were enrolled. The median follow-up was 28.7 months. In the intention-to-treat analysis, the median PFS and overall survival were 15.1 (95% CI, 8.4; -) and 36.3 (95% CI, 25.6; -) months, respectively. The overall response rate to induction was 69%. One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subsequently received a reduced-intensity conditioning allograft and seven a second ASCT followed by maintenance).ConclusionIn this prospective trial in patients with pPCL, we show that bortezomib, dexamethasone plus doxorubicin or cyclophosphamide induction followed by transplantation induces high response rates and appears to significantly improve PFS.

Published
2016

30. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

Author

Van de Wyngaert, Zoé, Nerich, Virginie, Fouquet, Guillemette, Chrétien, Marie-Lorraine, Caillot, Denis, Azar, Nabih, Garderet, Laurent, Lenain, Pascal, Macro, Margaret, Bourhis, Jean-Henri, Belhocine, Ramdane, Jaccard, Arnaud, Karlin, Lionel, Bobin, Arthur, Moya, Niels, Systchenko, Thomas, Gruchet, Cecile, Giraud, Christine, Guidez, Stéphanie, Darras, Claire, Princet, Isabelle, Touzeau, Cyrille, Moreau, Philippe, Hulin, Cyrille, Deconinck, Erik, Limat, Samuel, and Leleu, Xavier

Abstract

Mobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerixafor might not be greater if the cost of complication management was considered. We performed a cost analysis of these two strategies. This multicentric observational study recruited patients with myeloma who underwent a first PBSC mobilization. We considered direct medical costs, including hospitalization, mobilization agents, apheresis, and supportive treatments. We included 111 patients, 54 and 57 in the HDCy and plerixafor groups, respectively. Cost of mobilization with HDCy was 5097?±?2982€ vs. 10958?±?1789€ for plerixafor (p?

Published
2020
Full Text
View/download PDF

33. Outbreak of Extended-Spectrum Beta-Lactamase Producing Enterobacter cloacae with High MICs of Quaternary Ammonium Compounds in a Hematology Ward Associated with Contaminated Sinks

Author

Chapuis, Angélique, primary, Amoureux, Lucie, additional, Bador, Julien, additional, Gavalas, Arthur, additional, Siebor, Eliane, additional, Chrétien, Marie-Lorraine, additional, Caillot, Denis, additional, Janin, Marion, additional, de Curraize, Claire, additional, and Neuwirth, Catherine, additional

Published
2016
Full Text
View/download PDF

34. Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Author

Guidez, Stephanie, Demarquette, Hélène, Caillot, Denis, Jurczyszyn, Artur J., Pegourie, Brigitte, Chretien, Marie Lorraine, Lancesseur, Charles, Karlin, Lionel, Joao, Cristina, Richez, Valentine, Garderet, Laurent, Ikhlef, Souhila, Royer, Bruno, Hulin, Cyrille, Banos, Anne, Voog, Eric, Stoppa, Anne-Marie, Benboubker, Lofti, Abildgaard, Niels, Le Du, Katell, Moreau, Philippe, Facon, Thierry, Zweegman, Sonja, Macro, Margaret, Gay, Francesca Marianatal, Terpos, Evangelos, and Leleu, Xavier

Published
2017
Full Text
View/download PDF

35. Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Author

Hulin, Cyrille, Macro, Margaret, Gourgou, Sophie, Arnulf, Bertrand, Lachenal, Florence, Lenoir, Caroline, Stoppa, Anne-Marie, Chretien, Marie Lorraine, Vincent, Laure, Perrot, Aurore, Moreau, Philippe, Karlin, Lionel, Fohrer, Cécile, Eveilard, Jean-Richard, Fontan, Jean, and Decaux, Olivier

Published
2017
Full Text
View/download PDF

36. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, Fouquet, Guillemette, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Bourquard, Pascal, Lenain, Pascal, Roussel, Muriel, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Frayfer, Jamile, Fitoussi, Olivier, Roos Weil, Damien, Eisenmann, Jean-Claude, Dorvaux, Véronique, Voog, Eric, Hulin, Cyrille, and Attal, Michel

Published
2017
Full Text
View/download PDF

37. Nosocomial Infections with IMP-19-Producing Pseudomonas aeruginosa Linked to Contaminated Sinks, France.

Author

Amoureux, Lucie, Riedweg, Karena, Chapuis, Angélique, Bador, Julien, Siebor, Eliane, Péchinot, André, Chrétien, Marie-Lorraine, de Curraize, Claire, and Neuwirth, Catherine

Subjects
NOSOCOMIAL infections, PSEUDOMONAS aeruginosa infections, INTEGRONS, ACHROMOBACTER, COMAMONAS testosteroni, PUBLIC health
Abstract

We isolated IMP-19-producing Pseudomonas aeruginosa from 7 patients with nosocomial infections linked to contaminated sinks in France. We showed that blaIMP-19 was located on various class 1 integrons among 8 species of gram-negative bacilli detected in sinks: P. aeruginosa, Achromobacter xylosoxidans, A. aegrifaciens, P. putida, Stenotrophomonas maltophilia, P. mendocina, Comamonas testosteroni, and Sphingomonas sp. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

38. Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients

Author

Rossi, Cédric, primary, Kanoun, Salim, additional, Berriolo-Riedinger, Alina, additional, Dygai-Cochet, Inna, additional, Humbert, Olivier, additional, Legouge, Caroline, additional, Chrétien, Marie Lorraine, additional, Bastie, Jean-Noel, additional, Brunotte, François, additional, and Casasnovas, René-Olivier, additional

Published
2014
Full Text
View/download PDF

39. Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Author

Fouquet, Guillemette, primary, Hebraud, Benjamin, additional, Garciaz, Sylvain, additional, Stoppa, Anne Marie, additional, Roussel, Murielle, additional, Caillot, Denis, additional, Chrétien, Marie Lorraine, additional, Arnulf, Bertrand, additional, Szalat, Raphael, additional, Garderet, Laurent, additional, Benajiba, Lina, additional, Pegourie, Brigitte, additional, Regny, Caroline, additional, Royer, Bruno, additional, Caulier, Alexis, additional, Touzeau, Cyrille, additional, Tessoulin, Benoit, additional, Fermand, Jean Paul, additional, Facon, Thierry, additional, Attal, Michel, additional, Loiseau, Hervé Avet, additional, Moreau, Philippe, additional, and Leleu, Xavier, additional

Published
2014
Full Text
View/download PDF

40. Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group

Author

Royer, Bruno, Diouf, Momar, Roussel, Murielle, Karlin, Lionel, Hulin, Cyrille, Arnulf, Bertrand, Macro, Margaret, Cailleres, Sylvie, Brion, Annie, Brechignac, Sabine, Belhadj, Karim, Chretien, Marie Lorraine, Wetterwald, Marc, Chaleteix, Carine, Tiab, Mourad, Leleu, Xavier, Frenzel, Laurent, Garderet, Laurent, Choquet, Sylvain, Fuzibet, jean Gabriel, Dauriac, Charles, Fornecker, luc-Matthieu, Benboubker, Lotfi, Facon, Thierry, Moreau, Philippe, Avet Loiseau, Herve, Minvielle, Stephane, and Marolleau, Jean Pierre

Published
2016
Full Text
View/download PDF

41. Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM

Author

van de Wyngaert, Zoe, Azar, Nabih, Lenain, Pascal, Macro, Margaret, Bourhis, Jean-Henri, Garderet, Laurent, Jaccard, Arnaud, Karlin, Lionel, Giraud, Christine, Guidez, Stéphanie, Hebraud, Benjamin, Roussel, Muriel, Marit, Gerald, Hulin, Cyrille, Deconinck, Eric, Attal, Michel, Moreau, Philippe, Caillot, Denis, Limat, Samuel, Leleu, Xavier, and Chretien, Marie-Lorraine

Published
2016
Full Text
View/download PDF

43. Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Guidez, Stéphanie, Fouquet, Guillemette, Demarquette, Hélène, Nudel, Morgane, Boyle, Eileen, Chretien, Marie Lorraine, Caillot, Denis, Karlin, Lionel, Hulin, Cyrille, Decaux, Olivier, Arnulf, Bertrand, Fohrer, Cécile, MACRO, Margaret, Lancesseur, Charles, Roussel, Murielle, Hebraud, Benjamin, Facon, Thierry, and Leleu, Xavier

Published
2015
Full Text
View/download PDF

44. Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Author

Demarquette, Hélène, Guidez, Stéphanie, Jurczyszyn, Artur J., Caillot, Denis, Pegourie, Brigitte, Chretien, Marie Lorraine, Lancesseur, Charles, Karlin, Lionel, Joao, Cristina M., Bories, Claire, Legros, Laurence, Garderet, Laurent, Ikhlef, Souhila, Escoffre, Martine, Royer, Bruno, Voillat, Laurent, Hulin, Cyrille, Banos, Anne, Voog, Eric G., Stoppa, Anne-Marie, Benboubker, Lofti, Abildgaard, Niels, Le Du, Katell, Moreau, Philippe, Facon, Thierry, Zweegman, Sonja, MACRO, Margaret, Gay, Francesca, Terpos, Evangelos, and Leleu, Xavier

Published
2015
Full Text
View/download PDF

45. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Veronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, and Facon, Thierry

Published
2015
Full Text
View/download PDF

46. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Author

Avet-Loiseau, Herve, Corre, Jill, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Robillard, Nelly, Leleu, Xavier, Hulin, Cyrille, Gentil, Catherine, Arnulf, Bertrand, Belhadj, Karim, Brechignac, Sabine, Garderet, Laurent, Karlin, Lionel, Marit, Gerald, Benboubker, Lotfi, Orsini-Piocelle, Frederique, Royer, Bruno, Drenou, Bernard, Tiab, Mourad, Lamy, Thierry, MACRO, Margaret, Richardson, Paul G., Anderson, Kenneth C, Faham, Malek, Facon, Thierry, Moreau, Philippe, Attal, Michel, and Munshi, Nikhil C.

Published
2015
Full Text
View/download PDF

48. Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Author

Leleu, Xavier, Fouquet, Guillemette, Hebraud, Benjamin, Garciaz, Sylvain, Stoppa, Anne-Marie, Roussel, Murielle, Caillot, Denis, Chretien, Marie-Lorraine, Arnulf, Bertrand, Szalat, Raphael, Garderet, Laurent, Benajiba, Lina, Pegourie, Brigitte, Regny, Caroline, Royer, Bruno, Caulier, Alexis, Touzeau, Cyrille, Tessoulin, Benoit, Fermand, Jean Paul, Facon, Thierry, Attal, Michel, Avet-Loiseau, Herve, and Moreau, Philippe

Published
2013
Full Text
View/download PDF

50. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.

Author

Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, and Du Myélome IIF

Subjects
Adult, Humans, Aged, Treatment Outcome, Retrospective Studies, France, Multiple Myeloma drug therapy
Abstract

Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited from an early access program. We conducted an observational, retrospective, multicenter study. Eligibility criteria were treatment of relapsed or refractory multiple myeloma (RRMM) in monotherapy in adult patients who have received at least three lines of therapy previously, including at least one immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody, and whose disease progressed during the last treatment period. The primary endpoint of the study is to assess the overall survival (OS). Between November 2019 and December 2020, 106 patients were treated with BM; 97 were eligible for the efficacy evaluation and 104 for safety. The median age was 66 (range, 37-82) years. High-risk cytogenetics were identified in 40.9% of patients. Fifty-five (56.7%) patients were triple-class refractory and 11 (11.3%) were penta-class refractory. The median number of prior lines of treatment was five (range, 3-12). The median number of BM cycles administered was three (range, 1-22). The overall response rate at best response was 38.1% (37/97). The median OS was 9.3 months (95% confidence interval [CI]: 5.9-15.3), and median progression-free survival was 3.5 months (95% CI: 1.9-4.7). The median duration of response was 9 months (range, 4.65-10.4). Treatment was delayed for 55 (52.9%) patients including 36.5% for treatment-related toxicity. Ophthalmic adverse events, mainly grade ≤2, were the most common toxicity (48%). The occurrence of keratopathy was 37.5%. Overall, our data are concordant with the results from DREAMM-2 in terms of efficacy and safety on a non-biased population.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results